William Blair Investment Management LLC Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

William Blair Investment Management LLC grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 485,268 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,440 shares during the quarter. William Blair Investment Management LLC owned 2.31% of ANI Pharmaceuticals worth $26,826,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp boosted its stake in shares of ANI Pharmaceuticals by 9.1% in the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock valued at $41,991,000 after purchasing an additional 58,698 shares during the period. Global Alpha Capital Management Ltd. boosted its stake in shares of ANI Pharmaceuticals by 16.4% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares during the period. Pacer Advisors Inc. boosted its stake in shares of ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after purchasing an additional 565,910 shares during the period. JPMorgan Chase & Co. lifted its stake in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after acquiring an additional 340,854 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock worth $25,373,000 after acquiring an additional 17,314 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Remove Ads

ANI Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:ANIP traded down $0.09 during trading on Friday, hitting $64.26. 519,758 shares of the company were exchanged, compared to its average volume of 240,757. The firm's 50 day moving average price is $59.39 and its 200-day moving average price is $58.17. The stock has a market capitalization of $1.40 billion, a P/E ratio of -116.84 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of recent research reports. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price target for the company. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $79.75.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $191,776 in the last ninety days. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.